Diagnosing diseases is basically the frontlines when it comes to fighting against illnesses and how effectively and efficiently this is done will affect how the rest of the battle goes. Unfortunately, diagnosis can be expensive, depending on the disease. Thanks to a new microchip, which can cost only $0.1 to create, this might not be a problem anymore.
The microchip in question was created by a team of engineers from Stanford who published their findings in the Proceedings of the National Academy of Sciences. Not only is the chip tiny, it’s also incredibly inexpensive to produce and can be manufactured at a large scale in a very short period of time.
“For the developing world, point-of-care (POC) diagnostics design must account for limited funds, modest public health infrastructure, and low power availability,” the paper reads. “To address these challenges, here we integrate microfluidics, electronics, and inkjet printing to build an ultra–low-cost, rapid, and miniaturized lab-on-a-chip (LOC) platform.”
Calling it the FNIP chip, the researchers created the device with three layers of varying expendability. As for how it is used, it’s basically a two-step process. First, the user would need to customize the configuration in order to suit the particular disease that needs to be diagnosed, Futurism reports. Next, the necessary samples for analysis can then be printed onto the top layer of the chip.
So, which diseases can this microchip detect? So far, the researchers tested it to analyze cancer fluid and succeeded. They also used it to diagnose immune cells and was able to pull off similar results as another diagnostic tool that would have cost $100,000 in comparison.
Before anyone gets too excited, however, the researchers are saying that it would take some time before the microchip becomes widely available. There are some hurdles to overcome first, including more tests to see if the platform is even safe to use.


Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Japan’s Top Banks to Gain Access to Anthropic’s Claude Mythos AI Model
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
Nvidia CEO Jensen Huang to Join Trump’s China Visit Amid AI Chip Tensions
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 



